Your session is about to expire
← Back to Search
Study Summary
This trial is studying the side effects and best dose of TRE-515 when given alone in treating patients with solid tumors.
- Cancer
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the intended outcome of this research?
"This 18-month medical trial's main measure of success is the incidence of dose-limiting toxicities. Other objectives include evaluating antitumor activity according to RECIST v1.1, characterizing minimum observed plasma concentration (TRE-515-Cmin), and maximum observed plasma concentration (TRE-515 Cmax)."
What is the headcount of individuals taking part in this investigation?
"Affirmative. Clinicaltrials.gov indicates that this clinical study has been actively recruiting since September 23, 2021 and is still on the lookout for 36 participants from two different sites."
Are there any available openings in this research project?
"According to the details found on clinicaltrials.gov, this medical study is presently recruiting patients; it was first advertised in September 2021 and was most recently updated at the end of July 2022."
What possible risks can patients expect when taking TRE-515?
"Due to the limited clinical data for TRE-515, our team at Power assigned it a score of 1 on the safety scale. This is because this trial is in Phase I and there is minimal evidence backing its efficacy or safety."
Share this study with friends
Copy Link
Messenger